Lobbying client · LD-2 disclosures
Horizon Therapeutics (Formally Known as Horizon Pharma)
District of Columbia
20 filings from 1 registrant · 2019–2023 · latest filed Jan 19, 2024
Reported on its behalf
$1.3M
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$1.3M
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Health Issues
HCR
20 filings
$1.3M on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
Bills named in the filings
Every bill reference extracted from the filings' activity descriptions.
- H.Res. 242 116th CongressAffirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.3 filingsthrough 2019
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Who did the lobbying
Every lobbyist named on this client's filings.
- Edolphus Towns Gray Global Advisors, LLCCovered position: Former Member of Congress 1983-201313 filingsthrough 2023
- Vincent Barnes Gray Global Advisors, LLC10 filingsthrough 2021
- Catherine Finnerty Gray Global Advisors, LLC4 filingsthrough 2022
- Hodari Cail Gray Global Advisors, LLC2 filingsthrough 2023
- Nkosi Bradley Gray Global Advisors, LLC
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: horizon-therapeutics-formally-known-as-horizon-pharma.